Scholar Rock Holding (SRRK) Return on Capital Employed (2018 - 2026)
Scholar Rock Holding's (SRRK) quarterly Return on Capital Employed came in at 99.87% in Q1 2026, down 3280.0% year-on-year from 3.14% in Q1 2025, and up 8.46% quarter-over-quarter from 109.1% in Q4 2025.
Scholar Rock Holding (SRRK) Return on Capital Employed (2018 - 2026) Analysis & Trends
Scholar Rock Holding's Return on Capital Employed history runs 9 years deep, the most recent figure standing at 99.87% for Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 3280.0% year-over-year to 99.87% in Q1 2026; TTM through Mar 2026 was 99.87%, a 3280.0% decrease from a year earlier, with the FY2025 full-year figure at 100.12%, down 2728.0% from the prior year.
- Return on Capital Employed grew to 99.87% in Q1 2026 per SRRK's latest filing, from 109.1% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 34.62% in Q3 2022 and bottomed at 141.01% in Q3 2024.
- The 5-year median for Return on Capital Employed is 69.04% (2023), against an average of 76.71%.
- Across the five-year window, Return on Capital Employed sank 7311 bps in 2024 and soared 2566 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 39.77% in 2022, then tumbled by 74 bps to 69.04% in 2023, then sank by 30 bps to 89.99% in 2024, then retreated by 21 bps to 109.1% in 2025, then gained by 8 bps to 99.87% in 2026.
- Per Business Quant, the three latest SRRK Return on Capital Employed figures stand at 99.87% (Q1 2026), 109.1% (Q4 2025), and 115.35% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Scholar Rock Holding | 6.30 Bn | 6.30 Bn | - | -99.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -99.87% |
| Dec 31, 2025 | -109.10% |
| Sep 30, 2025 | -115.35% |
| Jun 30, 2025 | -99.99% |
| Mar 31, 2025 | -67.07% |
| Dec 31, 2024 | -89.99% |
| Sep 30, 2024 | -141.01% |
| Jun 30, 2024 | -97.91% |
| Mar 31, 2024 | -75.18% |
| Dec 31, 2023 | -69.04% |
| Sep 30, 2023 | -67.90% |
| Jun 30, 2023 | -59.48% |
| Mar 31, 2023 | -54.13% |
| Dec 31, 2022 | -39.77% |
| Sep 30, 2022 | -34.62% |
| Jun 30, 2022 | -40.19% |
| Mar 31, 2022 | -43.54% |
| Dec 31, 2021 | -54.79% |
| Sep 30, 2021 | -48.15% |
| Jun 30, 2021 | -38.38% |